2. Signaling Pathways
  3. Anti-infection
  4. Virus Protease

Virus Protease

Virus Protease

Related Products

PDF 0.37 MB

Viral proteases are enzymes encoded by the genetic material (DNA or RNA) of viral pathogens. Viral proteases catalyze the cleavage of specific peptide bonds in viral polyprotein precursors or in cellular proteins. Viral proteases may use different catalytic mechanisms involving either serine, cysteine or aspartic acid residues to attack the scissile peptide bond. Selective recognition of these sequence patterns by a complementary substrate binding site of the enzyme ensures a high degree of specific recognition and cleavage.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the cause of the respiratory illness coronavirus disease 2019 (COVID-19). Initial spike protein priming by transmembrane protease, serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2. After a SARS-CoV-2 virion attaches to a target cell, the cell's protease TMPRSS2 cuts open the spike protein of the virus, exposing a fusion peptide.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-169102
    CHIKV nsP2 protease-IN-1
    		Inhibitor
    CHIKV nsP2 protease-IN-1(compound J13) is an oral active non-structural protein 2 protease inhibitor with the EC50 of 0.39 μM aganist of CHIKV S27. CHIKV nsP2 protease-IN-1 can be used for study of Chikungunya virus.
    CHIKV nsP2 protease-IN-1
  • HY-181991
    IRBM-Z-2
    		Inhibitor
    IRBM-Z-2 is a non-competitive, orally active Zika virus (ZIKV) NS2B-NS3 protease inhibitor, with IC50 values of 0.04 μM and 3.1 μM against the wild-type and I156T mutant strains, respectively. IRBM-Z-2 exhibits broad-spectrum anti-flavivirus potential, with IC50 values of 2.1 μM and 0.09 μM against the NS2B-NS3 proteases of dengue virus 2 (DENV2) and West Nile virus (WNV), respectively. IRBM-Z-1 inhibits ZIKV replication and alleviates virus-induced cytopathic effects. IRBM-Z-1 can be used in studies related to ZIKV infection.
    IRBM-Z-2
  • HY-178480
    SARS-CoV-2 Mpro-IN-49
    		Inhibitor
    SARS-CoV-2 Mpro-IN-49 (Compound 22e) is a potent SARS-CoV-2 main protease (Mpro) inhibitor (IC50=0.087 μM). SARS-CoV-2 Mpro-IN-49 is promising for research of SARS-CoV-2 and coronavirus.
    SARS-CoV-2 Mpro-IN-49
  • HY-B0182R
    Carmofur (Standard)
    		Inhibitor
    Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).
    Carmofur (Standard)
  • HY-175279
    CHIKV nsP2 protease-IN-3
    		Inhibitor
    CHIKV nsP2 protease-IN-3 (Compound 5) is an irreversible covalent inhibitor targeting the nonstructural protein 2 (nsP2) cysteine protease of chikungunya virus (CHIKV) (IC50=0.5 μM). CHIKV nsP2 protease-IN-3 inhibits viral RNA replication. CHIKV nsP2 protease-IN-3 is promising for research of alphaviruses.
    CHIKV nsP2 protease-IN-3
  • HY-180369
    SIMR-2418
    		Inhibitor
    SIMR-2418 is an effective inhibitor of the main protease (Mpro) of SARS-CoV-2, with an IC50 value of 20.7 μM. SIMR-2418 can be used for research on SARS-CoV-2 virus infection.
    SIMR-2418
  • HY-10467
    HCV-796 analog
    		Inhibitor
    HCV-796 analog is a potent NS5B inhibitor that binds to the palm II site. HCV-796 analog is promising for research of hepatitis C (HCV) infections.
    HCV-796 analog
  • HY-168917
    9-Aminominocycline
    		Inhibitor
    9-Aminominocycline (9-AMN) is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC50 of 4.55 µM and 4.15 µM. 9-Aminominocycline inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC50 of 1.04 µM and 2.35 µM.
    9-Aminominocycline
  • HY-170886
    SARS-CoV-2 Mpro-IN-36
    		Inhibitor
    SARS-CoV-2 Mpro-IN-36 (Compound 6d) is an inhibitor of SARS-CoV-2 Mpro with an IC50 of 110 nM. SARS-CoV-2 Mpro-IN-36 exhibits antiviral activity with an EC50 of 1.6 μM.
    SARS-CoV-2 Mpro-IN-36
  • HY-174251
    (±)-Tuaimenal A
    		Inhibitor
    (±)-Tuaimenal A ((+)-1) is a secondary metabolite and a derivative of Sesamol (HY-N1417). (±)-Tuaimenal A has potent inhibitory activity against SARS-CoV-2 3CLpro with an IC50 of 33.3  μM. (±)-Tuaimenal A can be used for SARS-CoV-2 infection research.
    (±)-Tuaimenal A
  • HY-180910
    SARS-CoV-2 Mpro-IN-53
    		Inhibitor
    SARS-CoV-2 Mpro-IN-53 (Compound 7) is a SARS-CoV-2 Mpro inhibitor. SARS-CoV-2 Mpro-IN-53 causes a decrease in Mpro radius of gyration.
    SARS-CoV-2 Mpro-IN-53
  • HY-106312
    Viroxime
    Viroxime is an antiviral agent.
    Viroxime
  • HY-106247
    AG-1859
    		Inhibitor
    AG-1859 is a viral protease inhibitor. AG-1859 can be used in the research of viral infection.
    AG-1859
  • HY-180458
    SARS-CoV-2 Mpro-IN-52
    		Inhibitor
    SARS-CoV-2 Mpro-IN-52 (compound 47) is a potent SARS-CoV-2 main protease (MPro) inhibitor (EC50 = 0.0099 µM) with antiviral activity. SARS-CoV-2 Mpro-IN-52 exhibits potent and broad-spectrum activity against MERS, OC43, 229E with EC50s of 0.00961, 0.138, and 0.117 µM. SARS-CoV-2 Mpro-IN-52 can be used for COVID-19 research.
    SARS-CoV-2 Mpro-IN-52
  • HY-183727
    SARS-CoV-2 Mpro-IN-59
    		Inhibitor
    SARS-CoV-2 Mpro-IN-59 is a competitive, nonpeptidic SARS-CoV-2 Mpro inhibitor. SARS-CoV-2 Mpro-IN-59 can be used for the research of covid-19.
    SARS-CoV-2 Mpro-IN-59
  • HY-106161R
    Rupintrivir (Standard)
    		Inhibitor
    Rupintrivir (Standard) is the analytical standard of Rupintrivir (HY-106161). This product is intended for research and analytical applications. Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC50 of 0.023 μM. Rupintrivirvr shows immune-modulatory effect.
    Rupintrivir (Standard)
  • HY-173575
    SARS-CoV-2 3CLpro-IN-31
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent SARS-CoV-2 3CL protease (3CLpro) inhibitor of with an IC50 value of 37.33 nM. SARS-CoV-2 3CLpro-IN-31 blocks viral polyprotein cleavage and inhibits SARS-CoV-2 replication. SARS-CoV-2 3CLpro-IN-31 is promising for research of SARS-CoV-2 infection.
    SARS-CoV-2 3CLpro-IN-31
  • HY-136967
    Mergocriptine
    		Ligand
    Mergocriptine (CBM36-733) is a dopamine receptor agonist and SARS-CoV-2 Mpro ligand. Mergocriptine regulates ambulatory activity.
    Mergocriptine
  • HY-100733R
    4E2RCat (Standard)
    		Inhibitor
    4E2RCat (Standard) is the analytical standard of 4E2RCat (HY-100733). This product is intended for research and analytical applications. 4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC50 of 13.5 μM.
    4E2RCat (Standard)
  • HY-N15268
    Koenine
    		Inhibitor
    Koenine is a carbazole alkaloid. It is predicted that Koenine has strong binding affinity and inhibitory ability to SARS-CoV-2 main protease (Mpro), which can be used in the research of anti-novel coronavirus drugs.
    Koenine
Cat. No. Product Name / Synonyms Application Reactivity